Navigation Links
Taking the pee? Cranberry juice fails to cut it
Date:8/24/2009

Current clinical evidence for using cranberry juice to combat urinary tract infections is 'unsatisfactory and inconclusive', according to Raul Raz.

"An apple a day..." Not all medical problems require a state-of-the-art solution, and it would be nice to think that products from the corner shop could treat a widespread and uncomfortable ailment. Cranberry juice and related products have been touted as a simple solution for urinary tract infections, but Raul Raz, a member of F1000 Medicine, finds little to support this claim.

Urinary tract infections (UTIs) are a common complaint. Between 10% and 20% of women will suffer a UTI at least once, and a third of these will experience it recurrently. Some recent studies support the use of cranberry as a preventative, but Dr Raz, Director of Infectious Diseases at the Technion School of Medicine in Israel, and his associate Faculty Member, Hana Edelstein, advise the medical community that "cranberry should no longer be considered as an effective [preventative] for recurrent UTIs".

Cranberry contains hundreds of compounds, and it has been difficult to determine which might be responsible for any therapeutic effect, hindering its adoption. Raz and Edelstein point to differences in clinical trial design and the lack of standardization for doses and formulation. There is a range of potential side-effects including stomach upsets and weight gain. Cranberry can also interact badly with other medicines such as Warfarin, commonly used to treat heart disease.

In any event, up to 55% of patients discontinue cranberry therapy after a short time. It would seem that the public have already voted with their feet.


'/>"/>

Contact: Kathleen Wets
kathleen@f1000.com
44-207-323-0323
Faculty of 1000: Biology and Medicine
Source:Eurekalert

Page: 1

Related medicine news :

1. Taking up music so you can hear
2. Taking dex can improve high altitude exercise capacity in certain climbers
3. Taking the needles sting out of diabetes
4. Mathematics taking guesswork out of plastic surgery tissue transfer
5. Looking to Shape Up for Summer? The Solution May Be the Steps Youre Already Taking
6. Swine Flu Vaccine Taking Longer Than Expected
7. Drug Limits Stomach Trouble in Patients Taking Low-Dose Aspirin
8. Looking to Shape up for Summer? The Solution May be the Steps Youre Already Taking
9. Taking Aim at Relapse of Leukemia in Kids
10. Value of Taking Aspirin to Cut Heart Risk Varies
11. Financial Distress Taking Toll on Employee Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: